Back to Home
Video

Module 2: Unmaking The Potential of Liquid Biopsy and The Evolving Progress in the Management of Small Cell Lung Cancer

Release Date

April 30, 2026

Expiration Date

May 1, 2027

Credits

1.75 CME, NCPD

Specialties

Lung Cancer, Medical Oncology+4 more

Activity Overview

This educational activity is an archive of the live conference held from January 23 to 25, 2026.

Target Audience

This educational activity is intended for oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, clinical investigators, fellows, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

  • Evaluate efficacy and safety data from recent clinical trials on established and emerging therapeutic approaches for lung cancer.
  • Integrate the latest clinical evidence and guideline recommendations into the development of personalized treatment plans for patients with lung cancer.
      Module 2: Unmaking The Potential of Liquid Biopsy and The Evolving Progress in the Management of Small Cell Lung Cancer

      GET STARTED WITH THIS PROGRAM:

      Register now to gain access to this program.

      Create AccountAlready Registered? Login Here

      Accreditation/Credit Designation

      Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.

      Acknowledgment of Commercial Support

      This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corp; Merck Sharp & Dohme LLC; Partner Therapeutics, Inc; and Revolution Medicines.

      Follow Us on Social Media!

      Related Content

      Course

      Module 2: Unmaking The Potential of Liquid Biopsy and The Evolving Progress in the Management of Small Cell Lung Cancer

      Create Account